See more : Delivery Technology Solutions, Inc. (DTSL) Income Statement Analysis – Financial Results
Complete financial analysis of Indivior PLC (INDV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Indivior PLC, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Coeptis Therapeutics, Inc. (COEP) Income Statement Analysis – Financial Results
- Black Box Limited (BBOX.BO) Income Statement Analysis – Financial Results
- Padmanabh Industries Limited (PADMAIND.BO) Income Statement Analysis – Financial Results
- Coop Opsparing Modig (COIMOD.CO) Income Statement Analysis – Financial Results
- Newgioco Group, Inc. (NWGIW) Income Statement Analysis – Financial Results
Indivior PLC (INDV)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.indivior.com
About Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.09B | 884.63M | 777.48M | 689.68M | 815.16M | 959.92M | 1.15B | 968.89M |
| Cost of Revenue | 186.00M | 168.87M | 137.61M | 116.19M | 165.11M | 134.68M | 122.90M | 110.81M |
| Gross Profit | 907.00M | 715.75M | 639.87M | 573.49M | 650.05M | 825.25M | 1.03B | 858.08M |
| Gross Profit Ratio | 82.98% | 80.91% | 82.30% | 83.15% | 79.75% | 85.97% | 89.30% | 88.56% |
| Research & Development | 106.00M | 70.69M | 51.11M | 42.64M | 55.04M | 63.99M | 93.49M | 108.98M |
| General & Administrative | 575.00M | 545.00M | 239.00M | 447.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 236.00M | 218.00M | 192.00M | 202.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 811.00M | 439.86M | 404.96M | 437.05M | 385.25M | 444.14M | 508.40M | 411.18M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 911.00M | 510.55M | 456.07M | 479.69M | 440.29M | 508.14M | 601.89M | 520.16M |
| Cost & Expenses | 1.10B | 679.43M | 593.68M | 595.88M | 605.40M | 642.82M | 724.79M | 630.97M |
| Interest Income | 43.00M | 18.00M | 1.00M | 7.00M | 24.92M | 16.24M | 7.35M | 0.00 |
| Interest Expense | 37.00M | 29.00M | 26.00M | 24.00M | 20.77M | 29.61M | 51.47M | 51.00M |
| Depreciation & Amortization | 28.00M | 20.62M | 21.62M | 27.72M | 29.08M | 15.28M | 13.66M | 12.82M |
| EBITDA | 68.61M | -44.18M | 233.93M | -128.98M | 214.00M | 310.42M | 436.97M | 149.27M |
| EBITDA Ratio | 6.28% | 25.53% | 26.42% | 17.62% | 29.30% | 34.63% | 38.06% | 36.20% |
| Operating Income | -4.00M | 205.20M | 183.80M | 93.81M | 209.76M | 317.11M | 423.32M | 337.92M |
| Operating Income Ratio | -0.37% | 23.20% | 23.64% | 13.60% | 25.73% | 33.03% | 36.87% | 34.88% |
| Total Other Income/Expenses | 5.00M | -10.00M | -23.00M | -17.00M | -22.85M | -14.00M | -56.00M | -51.00M |
| Income Before Tax | 1.00M | -93.27M | 186.75M | -184.41M | 186.92M | 265.53M | 143.91M | 89.75M |
| Income Before Tax Ratio | 0.09% | -10.54% | 24.02% | -26.74% | 22.93% | 27.66% | 12.53% | 9.26% |
| Income Tax Expense | -1.00M | -41.24M | -14.74M | -26.65M | 47.77M | 2.87M | 82.98M | 57.69M |
| Net Income | 2.00M | -52.04M | 205.00M | -157.76M | 139.15M | 262.67M | 60.92M | 32.05M |
| Net Income Ratio | 0.18% | -5.88% | 26.37% | -22.87% | 17.07% | 27.36% | 5.31% | 3.31% |
| EPS | 0.01 | -0.37 | 1.38 | -1.08 | 0.95 | 1.81 | 0.42 | 0.22 |
| EPS Diluted | 0.01 | -0.37 | 1.31 | -1.08 | 0.92 | 1.75 | 0.41 | 0.22 |
| Weighted Avg Shares Out | 137.31M | 139.01M | 145.66M | 146.57M | 146.05M | 145.43M | 144.23M | 143.97M |
| Weighted Avg Shares Out (Dil) | 141.80M | 139.01M | 154.23M | 146.57M | 151.07M | 150.23M | 149.70M | 148.64M |
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Indivior PLC(INDV) Shareholders
Investors in Indivior PLC Should Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming Deadlines - INDV
Indivior PLC Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 1, 2024 to Discuss Your Rights - INDV
FINAL INDV DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Indivior PLC Investors to Join the Class Action Lawsuit!
Indivior PLC Investors: Please contact the Portnoy Law Firm to recover your losses. October 1, 2024 Deadline to file Lead Plaintiff Motion
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 1, 2024 in Indivior Lawsuit – INDV
Shareholders that lost money on Indivior PLC(INDV) should contact Levi & Korsinsky about pending Class Action - INDV
Investors who lost money on Indivior PLC(INDV) should contact Levi & Korsinsky about pending Class Action - INDV
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC (INDV)
Source: https://incomestatements.info
Category: Stock Reports